Discovery & Development Drug Discovery, COVID-19

Trial Ready

The University of Oxford receives its first batch of AZD1222, a coronavirus vaccine candidate.

06/19/2020 | Quick Read

Academics at the Jenner Institute at the University of Oxford, UK, have received 4000
doses of AZD1222 (formerly known as ChAdOx1 nCoV-19) for use in a Phase 2/3
trial from Italian contract manufacturer Advent, part of the IRBM Group.

Find out more here

Credit: Advent, IRBM

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.